A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma

OBJECTIVE: IRX-2, a primary cell-derived biologic with pleotropic immune activity, was shown to induce increased lymphocyte infiltrations into the tumor of patients with head and neck squamous cell cancer (HNSCC) after 10 days of neoadjuvant therapy (Berinstein et al. 2011). In the same patients enr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Whiteside, Theresa L., Butterfield, Lisa H., Naylor, Paul H., Egan, James E., Hadden, John W., Baltzer, Lorraine, Wolf, Gregory T., Berinstein, Neil L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer-Verlag 2011
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3721338/
https://ncbi.nlm.nih.gov/pubmed/22109700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-011-1136-x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak